The Manufacturers Life Insurance Company Takes Position in Calumet, Inc. $CLMT

The Manufacturers Life Insurance Company purchased a new position in shares of Calumet, Inc. (NASDAQ:CLMT) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 29,852 shares of the oil and gas company’s stock, valued at approximately $1,075,000.

Other hedge funds also recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in Calumet during the first quarter valued at $14,066,000. Two Seas Capital LP bought a new stake in shares of Calumet in the second quarter valued at $238,442,000. BlackRock Inc. raised its stake in shares of Calumet by 5.1% in the second quarter. BlackRock Inc. now owns 5,234,106 shares of the oil and gas company’s stock valued at $188,532,000 after buying an additional 253,578 shares during the period. Bank of America Corp DE lifted its position in shares of Calumet by 65.1% during the 1st quarter. Bank of America Corp DE now owns 1,153,744 shares of the oil and gas company’s stock valued at $41,419,000 after buying an additional 454,985 shares during the last quarter. Finally, one8zero8 LLC purchased a new position in shares of Calumet during the 2nd quarter valued at $6,700,000. Institutional investors own 34.41% of the company’s stock.

Trending Headlines about Calumet

Here are the key news stories impacting Calumet this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its Q3 2026 EPS estimate to $0.62 from $0.60, Q4 to $0.24 from $0.22, FY2026 to $0.17 from $0.12, and FY2027 to $1.11 from $0.59. Its $75 price target implies substantial upside from the stock’s recent trading level. HC Wainwright earnings estimate report
• Positive Sentiment: The upward revisions suggest HC Wainwright expects stronger profitability over the next several quarters, potentially reflecting improved operating performance or business conditions. The revised FY2027 forecast is notably above the broader current-year consensus estimate of $0.46 per share. Calumet stock price expected to rise
• Neutral Sentiment: Calumet announced plans to attend the H.C. Wainwright conference. The event could provide investors with updates on strategy and operations, but no new financial information was disclosed in the announcement. Calumet conference announcement
• Neutral Sentiment: A Zacks analysis compared Calumet’s year-to-date performance with TXO Partners and the broader oil-and-energy sector. The article provides relative-performance context but does not indicate a new company-specific catalyst. Zacks Calumet sector performance analysis
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Calumet investors. Although the announcement does not establish wrongdoing, the prospect of litigation or regulatory concerns may weigh on sentiment and introduce uncertainty. Pomerantz investor investigation

Insider Activity

In related news, Director Daniel Sajkowski sold 4,240 shares of Calumet stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $36.16, for a total transaction of $153,318.40. Following the completion of the sale, the director owned 77,718 shares of the company’s stock, valued at approximately $2,810,282.88. This trade represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.15% of the company’s stock.

Wall Street Analysts Forecast Growth

CLMT has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Calumet in a research note on Friday, August 7th. TD Cowen upped their price objective on shares of Calumet from $34.00 to $40.00 and gave the company a “hold” rating in a report on Wednesday, August 12th. Citigroup reiterated a “buy” rating on shares of Calumet in a research report on Monday, August 10th. The Goldman Sachs Group lifted their target price on shares of Calumet from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright boosted their price target on shares of Calumet from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.75.

Calumet Trading Down 0.7%

Calumet stock opened at $53.13 on Friday. Calumet, Inc. has a 1-year low of $16.75 and a 1-year high of $54.69. The firm has a market capitalization of $4.67 billion, a PE ratio of -34.28 and a beta of 0.72. The firm’s 50 day simple moving average is $43.76 and its 200 day simple moving average is $36.21.

Calumet (NASDAQ:CLMT) last announced its quarterly earnings results on Friday, August 7th. The oil and gas company reported ($1.09) EPS for the quarter, missing the consensus estimate of $0.07 by ($1.16). The business had revenue of $1.45 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Calumet’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the firm posted ($1.70) earnings per share. Research analysts forecast that Calumet, Inc. will post 0.48 earnings per share for the current year.

About Calumet

Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.

Calumet’s product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.